Learn how BCMA CAR-T therapy works to treat multiple myeloma. This easy-to-understand guide explains benefits, side effects, and what patients can expect from this breakthrough immunotherapy.
Multiple myeloma (MM) remains an incurable blood cancer with high relapse and drug resistance rates. Discover how emerging immunotherapies are reshaping treatment and offering new hope for patients.
The latest clinical data demonstrate that Carvykti reduces the risk of death by 45% after three years of follow-up.
Carvykti, a US FDA approved CAR T-cell therapy, has been approved in China for the treatment of r/r MM.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.